NCT04670796View on ClinicalTrials.gov

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

June 4, 2021

Study Completion Date

June 4, 2021

Conditions
Healthy
Interventions
DRUG

HLX02

subject receive one dose of HLX02

DRUG

EU-sourced Trastuzumab (Herceptin®)

subject receive one dose of EU-sourced Trastuzumab (Herceptin®)

DRUG

US-licensed Trastuzumab (Herceptin®)

subject receive one dose of US-licensed Trastuzumab (Herceptin®)

Trial Locations (1)

Unknown

The Second Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY

NCT04670796 - A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects | Biotech Hunter | Biotech Hunter